Suppelemntary table Demographic and clinical characteristics of patients with anti-MAG polyneuropathy

Patient (sex, age) / Neuropathy duration (years)* / Hematological
disease / Responder§ / Relapsing¶ / Follow-up (years)
1 (M, 44) / 0.5 / Trombocitosis / yes / yes / 3
2 (M, 61) / 5 / Lymphoma / yes / yes / 2
3 (F, 70) / 15 / Waldenström / no / n.a. / 1
4 (F, 60) / 4 / IgM MGUS / yes / yes / 3
5 (F, 69) / 1 / IgM MGUS / yes / no / 5
6 (F, 53) / 2 / IgM MGUS / yes / no / 5
7 (M, 65) / 3 / IgM MGUS / yes / no / 4
8 (F, 61) / 16 / IgM MGUS / yes / no / 2
9 (M, 60) / 1 / IgM MGUS / yes / yes / 3
10 (F, 65) / 15 / IgM MGUS / yes / no / 3
11 (M, 67) / 4 / IgM MGUS / yes / no / 3
12 (M, 74) / 4 / IgM MGUS / no / n.a. / 1
13 (M, 68) / 3 / IgM MGUS / yes / yes / 3
14 (M, 71) / 19 / IgM MGUS / no / n.a. / 1
15 (M, 64) / 17 / IgM MGUS / no / n.a. / 1
16 (M, 77) / 8 / IgM MGUS / yes / no / 1
17 (M, 75) / 2 / IgM MGUS / yes / no / 1
18 (F, 73) / 6 / IgM MGUS / no / n.a. / 1
19 (F, 71) / 1 / IgM MGUS / yes / no / 1
20 (F, 54) / 1 / IgM MGUS / no / n.a. / 1
21 (M, 73) / 10 / IgM MGUS / no / n.a. / 1
22 (M, 48) / 2 / IgM MGUS / yes / yes / 3
23 (F, 65) / 7 / IgM MGUS / yes / no / 2

MGUS, monoclonal gammopathy of undetermined significance; *from the onset of neurological symptoms; §patient who improved at month 12, after rituximab therapy, by at least one point in at least two of the following clinical scales: MRC sumscore8, INCAT Disability Scale,9 and INCAT sensory sumscore;10 ¶clinical deterioration was defined as worsening by one point in at least two scales from the onset of neurological symptoms; n.a., not applicable